Susan A. Knudson
2022 - Conatus Pharmaceuticals
In 2022, Susan A. Knudson earned a total compensation of $681.2K as Executive Vice President, Chief Operations Officer & Chief Financial Officer at Conatus Pharmaceuticals, a 26% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,450 |
|---|---|
| Option Awards | $28,037 |
| Salary | $465,750 |
| Total | $681,237 |
Knudson received $465.8K in salary, accounting for 68% of the total pay in 2022.
Knudson also received $187.5K in non-equity incentive plan and $28K in option awards.
Rankings
In 2022, Susan A. Knudson's compensation ranked 3,833rd out of 5,756 executives tracked by ExecPay. In other words, Knudson earned more than 33.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,833 out of 5,756 | 33rd |
Division Manufacturing | 2,167 out of 3,133 | 31st |
Major group Chemicals And Allied Products | 1,045 out of 1,419 | 26th |
Industry group Drugs | 981 out of 1,320 | 26th |
Industry Pharmaceutical Preparations | 718 out of 966 | 26th |
Source: SEC filing on May 1, 2023.
Knudson's colleagues
We found two more compensation records of executives who worked with Susan A. Knudson at Conatus Pharmaceuticals in 2022.
News
Conatus Pharmaceuticals CFO Susan Knudson's 2022 pay jumps 26% to $681K
May 1, 2023
Conatus Pharmaceuticals CEO Steven Mento's 2020 pay slips 5% to $1.3M
April 15, 2021
Pfenex CEO Evert Schimmelpennink's 2019 pay rises 11% to $1.8M
April 1, 2020
Neothetics CEO Saundra Pelletier's 2018 pay jumps 401% to $8.3M
April 24, 2019
Pfenex CEO Evert Schimmelpennink's 2018 pay jumps 47% to $1.6M
April 4, 2019